At the 2025 BIO Asia–Taiwan Innovation Forum SA-2, leading U.S.-based experts in advanced gene and cell therapy gathered to share cutting-edge technologies and commercialization strategies that are redefining the future of CGT:

Prime Medicine: Precise Prime Editing unlocks rare disease & liver gene therapy potential.
Sana Biotech: Hypoimmune cells offer single-dose diabetes therapy—no immunosuppression needed.
Charles River: Urges early QC and decentralized manufacturing to boost access.
Iovance: First FDA-approved TIL therapy for solid tumors shows 31.4% ORR and long-term survival.

The global CGT market is projected to surpass USD 40.6 billion by 2027. Now is the time to prepare for what's next!
Learn more: https://reurl.cc/DOy5dO

#Globalbio #BIOAsiaTaiwan2025 #CGT #GeneEditing #CellTherapy #Hypoimmune #TIL #DecentralizedManufacturing #BiotechInnovation #RegenMed #BIOAsia